Insurance Issues

[gwenstefni]

For individuals with bleeding disorders, and especially those with hemophilia, treatment can be a tremendously heavy financial burden. In fact, the treatment of hemophilia ranks among the most expensive chronic diseases in the United States. New technology has led to remarkable advances in improving the safety of new blood products, but these technologies have come at ever-increasing costs.It is difficult to separate these cost increases from the overall cost increase in healthcare nationwide; however, research and development for many of these specialized products come with a huge price tag. Current factor concentrates are among the most costly therapies in the world, with a total annual cost per person ranging from $60,000 to $150,000. Complications such as major surgery, undergoing immune tolerance for an inhibitor, HIV/AIDS and/or hepatitis treatments, can increase these costs exponentially.The state of insurance reimbursement today is constantly changing to meet this competitive environment. Patients and medical professionals alike are finding the system difficult to manage, complex and often confusing. While organizations and treatment professionals can educate people to better understand insurance, it ultimately falls on individuals to manage their own healthcare reimbursement.
----------------------------
Gwenstefni